March 2024: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) in combination with obinutuzumab has been granted accelerated approval by the Food and Drug Administration for the treatment of relapsed or refractory follicular lymphoma (FL)..
If you're reading this, you or maybe one of your loved ones is on a journey that no one ever plans to take—the path of facing cancer. We understand that this road is filled with uncertainties, fears, and moments when it feel..
Atklājiet zinātni par CAR T šūnu terapijas ārstēšanu Indijā! Izpētiet, kā šī revolucionārā ārstēšana pārvērš jūsu imūnās šūnas par vēža apkarošanas līdzekļiem. Lasiet mūsu emuāru tagad, lai uzzinātu vairāk par šo brīnumaino terapiju un to, kā...
Have you ever wondered if there is a powerful way to fight cancer? Now just imagine if one day you found a ray of hope in your fight against cancer, a treatment that uses the power of your body's own immune system to target an..
2023. gada maijs: Pieaugušiem pacientiem ar augstas pakāpes B-šūnu limfomu (HGBL), kas nav norādīta citādi (NOS) vai difūzu lielo B šūnu limfomu (DLBCL), kuri iepriekš nav saņēmuši ārstēšanu un kuriem ir starptautiska prognostiskā indeksa.
SHANGHAI, CHINA, October 10, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, announced that the Na..
Feb 2023: The results of the trial demonstrated that a novel chimeric antigen receptor T-cell therapy elicited a response in adults with advanced large B-cell lymphoma who had relapsed following prior CAR-T. According to stati..
Feb 2023: Accelerated approval is granted by FDA to pirtobrutinib (Jaypirca, Eli Lilly and Company) for relapsed or refractory mantle cell lymphoma. In BRUIN (NCT03740529), an open-label, multicenter, single-arm trial of pirtobr..
Feb 2023: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) is approved by FDA for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). SEQUOIA was used to assess effectiveness in CLL/SLL patients who had not recei..
2022. gada novembris: Pārtikas un zāļu pārvalde ir apstiprinājusi doksorubicīna, vinkristīna, etopozīda, prednizona un ciklofosfamīda kombināciju ar brentuksimaba vedotīnu (Adcetris, Seagen, Inc.) lietošanai bērniem un.